A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
A phase 2 trial of Pimicotinib (ABSK021) in pancreatic ductal adenocarcinoma, run by Abbisko Therapeutics Co, Ltd, now recruiting.
Overview
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT06111274 by Abbisko Therapeutics Co, Ltd, with 82 participants planned, started 2023-10-17 and due to reach its primary completion in 2025-12-30. Interventions recorded: Pimicotinib (ABSK021).
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Shares Abbisko Therapeutics and the tag pipeline.
- TrialA Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Shares Abbisko Therapeutics and the tag pipeline.
- TrialABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Shares Abbisko Therapeutics and the tag pipeline.
- TrialStudy of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Shares Abbisko Therapeutics and the tag pipeline.
- TrialGlufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialFOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.